OncoMatch/Clinical Trials/NCT07257523

Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer

Is NCT07257523 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for pancreatic neoplasm.

"This prospective, single-arm phase II study aims to evaluate the efficacy and safety of carbon ion radiotherapy in frail patients with histologically confirmed, non-metastatic pancreatic cancer who are not eligible for surgery or systemic chemotherapy. Frail status is defined as a Clinical Frailty Scale (CFS) score ≥4 or the presence of significant medical comorbidities limiting aggressive treatment. Carbon ion radiotherapy, known for its superior dose distribution and high linear energy transfer, may offer improved tumor control with acceptable toxicity in this vulnerable population. This study will assess overall survival, progression-free survival, local control, toxicity, and quality of life.